These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2114783)

  • 1. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation.
    Marcus FI
    Am J Cardiol; 1990 Aug; 66(3):366-7. PubMed ID: 2114783
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Persistent atrial flutter induced by propafenone (Rytmonorm)].
    Fazekas T; Kiss J; Pap I; Rudas L
    Orv Hetil; 1994 Aug; 135(33):1819-22. PubMed ID: 8072758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation.
    Capucci A; Villani GQ; Piepoli MF; Aschieri D
    Curr Opin Cardiol; 1999 Jan; 14(1):4-8. PubMed ID: 9932201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.
    Feld GK; Chen PS; Nicod P; Fleck RP; Meyer D
    Am J Cardiol; 1990 Aug; 66(3):378-83. PubMed ID: 2114784
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
    Aliot E; Denjoy I
    Am J Cardiol; 1996 Jan; 77(3):66A-71A. PubMed ID: 8607394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
    Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
    Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
    Piccini JP; Kong DF
    Europace; 2011 Mar; 13(3):295-6. PubMed ID: 21345924
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.
    Chimienti M; Cullen MT; Casadei G
    Am J Cardiol; 1996 Jan; 77(3):60A-75A. PubMed ID: 8607393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of encainide in atrial fibrillation.
    Vlay SC; Reid PR
    Clin Cardiol; 1984 Sep; 7(9):498-502. PubMed ID: 6442224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encainide and flecainide in children: separating the wheat from the chaff.
    Perry JC; Garson A
    J Am Coll Cardiol; 1991 Aug; 18(2):366-7. PubMed ID: 1906903
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of antiarrhythmic agents in heart failure: implications of CAST.
    Gottlieb SS
    Am Heart J; 1989 Nov; 118(5 Pt 1):1074-7. PubMed ID: 2510486
    [No Abstract]   [Full Text] [Related]  

  • 14. Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias.
    Coumel P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():579-84. PubMed ID: 2125836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
    Podrid PJ
    Chest; 1985 Oct; 88(4):618-24. PubMed ID: 3930162
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation.
    Grey E; Silverman DI
    Pacing Clin Electrophysiol; 1993 Dec; 16(12):2235-40. PubMed ID: 7508600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
    Coyle JD; Schaal SF
    DICP; 1989 Jun; 23(6):478-9. PubMed ID: 2500783
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs for cardiac arrhythmias: new warning.
    Med Lett Drugs Ther; 1989 May; 31(792):48. PubMed ID: 2497313
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
    Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M
    Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic therapy--conventional wisdom challenged.
    Turakhia DP
    J Assoc Physicians India; 1990 Aug; 38(8):605. PubMed ID: 2123185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.